key: cord-1003281-pa6449iz
authors: Lavelle, Michael P.; Desai, Amar D.; Wan, Elaine Y.
title: Arrhythmias in the COVID-19 Patient
date: 2022-01-14
journal: Heart Rhythm O2
DOI: 10.1016/j.hroo.2022.01.002
sha: d800f2f09d63495863cb8de39317dbea586fd6d7
doc_id: 1003281
cord_uid: pa6449iz

Coronavirus disease 2019 (COVID-19) has encompassed the globe since it was first observed just under 2 years ago. While the disease is predominantly a respiratory illness, there have been observed complications throughout the various organ systems. Namely, cardiovascular complications, and, more specifically, arrhythmic complications have been described throughout the pandemic in patients with COVID-19. Management of atrial arrhythmias, ventricular arrhythmias and bradyarrhythmias in patients with COVID-19 infection has been largely guided by our prior experience in the management of these arrhythmias in similar patient populations without infection. However, this review aims to highlight the specific considerations as they pertain to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the various arrhythmic manifestations observed with this disease.

Coronavirus disease 2019 (COVID-19) has encompassed the globe since it was first observed 24 just under 2 years ago. While the disease is predominantly a respiratory illness, there have been 25 observed complications throughout the various organ systems. Namely, cardiovascular 26 complications, and, more specifically, arrhythmic complications have been described throughout 27 the pandemic in patients with COVID-19. Management of atrial arrhythmias, ventricular 28 arrhythmias and bradyarrhythmias in patients with COVID-19 infection has been largely guided 29 by our prior experience in the management of these arrhythmias in similar patient populations 30 without infection. However, this review aims to highlight the specific considerations as they 31 pertain to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the various 32 arrhythmic manifestations observed with this disease. (Table 1) 5 . In a worldwide survey of 4,526 patients admitted to the hospital with COVID-19, a 60 cardiac arrhythmia was identified in 827 patients 6 . Unsurprisingly, cardiovascular comorbidities 61 such as hypertension (69%), diabetes mellitus (42%), coronary artery disease (24%) and 62 congestive heart failure (30%) were common in the patients who developed cardiac 63 arrhythmias 6 . More generally, arrhythmia in this patient population is associated with older age, 64 disease severity, history of congestive heart failure, and troponin levels 7 . While the exact 65 prevalence of cardiovascular complications in patients suffering from COVID-19 is not yet 66 known, previous studies have suggested that those with pre-existing cardiovascular disease might 67 be most susceptible to these types of complications 8-10 . One meta-analysis of 1,527 patients 68 J o u r n a l P r e -p r o o f Arrhythmic manifestations are just one aspect of the cardiac sequelae of COVID-19 and 92 there have been several proposed mechanisms. The angiotensin-converting enzyme 2 (ACE2) 93 receptor, the SARS-CoV-2 virus' receptor of cell entry, has been notably demonstrated to be 94 expressed in the heart at higher levels than in the lungs 17 . This may explain the nature of cardiac 95 complications of the disease, including cardiac arrhythmias 17,18 . A well-established risk factor for 96 the development of cardiac arrhythmias is myocardial ischemia 19 . Ischemia in myocytes results 97 in increases in extracellular potassium and increases in intracellular potassium which results in 98 significant alterations in action potentials and resultant arrhythmia 19 . Infection with SARS-CoV-99 2 is associated with high rates of severe pulmonary illness and acute respiratory distress 100 syndrome (ARDS) which is associated with substantial hypoxemia which can result in 101 myocardial ischemia, particularly in those with underlying cardiovascular disease 20 . SARS-CoV-102 2 infection has also been associated severe systemic inflammation and cytokine storm 21 . Several 103 of these inflammatory markers, specifically Interleukin (IL)-6, tumor necrosis factor (TNF) , 104 and IL-1, have been shown to prolong the ventricular action potential which also may be 105 responsible for the arrhythmogenesis seen in critically ill patients with COVID-19 22 . As a 106 possible underlying mechanism for this observation, rat and stem cell derived myocytes that 107 were bathed in serum derived from critically ill patients with COVID-19 were shown to have 108 perturbations of calcium homeostasis in vitro which can be pro-arrhythmic 23 . Interestingly, the 109 addition of canakinumab, an IL-1 antagonist, to the serum had no impact on the observed pro-110 arrhythmogenic calcium release, suggesting alternate pathways may be responsible for this 111 observation. 112

Myocardial damage may also result from mechanisms other than ischemia. Myocarditis 113 has been a well described clinical complication of patients with SARS-CoV-2 infection 24 . As the 114 J o u r n a l P r e -p r o o f spike protein of SARS-CoV-2 binds to ACE-2 on the surface of cells to gain entry and ACE-2 is 115 present on cardiomyocytes, this is one possible mechanism through which SARS-CoV-2 can 116 result in direct cardiomyocyte toxicity and cause myocarditis 24 . Myocarditis of all causes has 117 been associated with high rates of ventricular arrhythmias and is potentially responsible for some 118 of the arrhythmia associated with COVID-19 25 COVID-19, the overall incidence of atrial fibrillation (AF) and atrial flutter (AFl) as assessed by 134 manual chart review was 13% and 6.6% in those without a prior history of atrial arrhythmia 29 . In 135 this study, those with AF or AFl were more likely to be older and had higher inflammatory 136 markers (CRP and IL-6), as well as higher levels of markers of myocardial dysfunction (peak 137 troponin and B-type-natriuretic peptide) 29 . The presence of in-hospital AF or AFl was also 138 associated with increased mortality (46% vs. 26%, RR 1.78, p<0.01). Similarly, a large meta-139 analysis with a pooled total of 21,582 hospitalized patients with PCR confirmed COVID-19 140 found a prevalence of AF of 11% 30 . There was a 2.5-fold increase in the prevalence of AF in 141 those over age 60 compared to those younger than 60 and a 6-fold increase in the prevalence in 142 those with severe disease compared to those with milder disease 30 . Of the portion of studies 143

reporting mortality outcomes, the presence of AF was associated with an increase in all-cause 144 mortality (50.6% vs. 29.3%, OR 2.98 95% CI 1.91 -4.66) 30 . 145

There is also a growing body of evidence that a history of prior AF is associated with 146 There are significant management considerations that must be considered for atrial 161 arrhythmias from COVID-19 infection. AF is typically treated with a combination of rhythm 162 control, rate control and anticoagulation in patients without contraindications due to bleeding 163 risks 34 . It is worth noting that consideration for therapeutic anticoagulation with heparin, 164

regardless of atrial fibrillation, should be considered for all non-critically ill hospitalized patients 165

with COVID-19 based on recent data reporting an improved probability of organ-support free 166 survival to hospital discharge with therapeutic anticoagulation compared to prophylactic dose 35 . 167

Standard therapies for rate control consist of pharmacological management, typically with 168 calcium channel blockers or beta blockers. Due to possible concern of respiratory 169 bronchoconstriction with beta-blocker usage for patients with acute respiratory illness such as 170 COVID-19, calcium channel blockers are an alternative option as rate control agents 34,36 . It is 171 critical to be mindful of drug-drug interactions and the potential need to modify agents used for 172 rhythm control, as patients with COVID-19 are often treated with many additional medications 37 . channel-related mutations 59 . It is important to note, however, that management considerations are 325 specific to certain channelopathies. For instance, short QT syndrome and catecholaminergic 326 polymorphic ventricular tachycardia have not significant added concern COVID-19 apart from 327 avoiding electrolyte-related imbalances 52,60 . Specific guidance for cardiomyopathies and other 328 inherited conditions has also previously been described 61 . 329

As our experience with vaccination against SARS-CoV-2 continues to grow, the 330 management of cardiovascular complications related to vaccination will continue to evolve. Rare As we near the end of the pandemic phase of COVID-19, it is highly likely SARS-CoV-2 344 will remain endemic throughout the world. Thus, the lessons we learned during the acute phase 345 must be carried forward as we continue to build on our understanding and knowledge on the 346 presentation and management of COVID-19 disease. In particular, as outlined in this review, 347 there have been a variety of arrhythmic complications observed in patients infected with SARS-348

CoV-2. Current data on the presentation and management of these patients is largely limited to 349 small observational case series and case reports. Pooled data and larger registries would help 350 better inform the incidence and optimal management strategies in this patient population. J o u r n a l P r e -p r o o f

Please provide a list of the Key Findings from the article. The Key Findings should be brief bullets (each bullet may be up to 2-3 sentences). The Key Findings should be submitted in MS Word format as a separate file, rather than embedded in the main manuscript document. Please include a minimum of 3 Key Findings.

 Infection with COVID-19 has been associated with many extra-pulmonary manifestations, cardiac arrhythmias have become one of the more commonly reported. This review highlights the diagnosis and management of the most common arrhythmic manifestations associated with COVID-19.  Managing arrhythmias in patients with COVID-19 can bring a unique set of challenges not experienced in other patients with the same arrhythmia. These unique challenges are addressed with proposed management strategies.  In addition to the disease itself, there have been cardiovascular implications of the various therapeutics used to combat COVID-19 which are also highlighted in this manuscript.

Incidence of ARDS and outcomes 424 in hospitalized patients with COVID-19: a global literature survey

Calming the cytokine storm in COVID-19

Arrhythmic Risk, and 429 Inflammation: Mind the Gap! Circulation

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the 431 effect of Canakinumab

Recognizing COVID-19-related myocarditis: The possible 433 pathophysiology and proposed guideline for diagnosis and management

Ventricular Arrhythmias in Myocarditis

Relationships With Myocardial Inflammation

Cardiac Corrected QT Interval Changes Among Patients Treated for 438 COVID-19 Infection During the Early Phase of the Pandemic

COVID-19 441 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical 442 implications

Atrial Arrhythmias in Patients with Severe COVID-19

Atrial Fibrillation in Patients Hospitalized With COVID-19: 446 Incidence, Predictors, Outcomes, and Comparison to Influenza

Prevalence of Atrial Fibrillation and Associated Mortality Among 449 Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. Front 450 Cardiovasc Med

Implications of atrial fibrillation on the clinical course and outcomes of 452 hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study

Permanent atrial fibrillation portends poor outcomes 455 in hospitalized patients with COVID-19: A retrospective observational study

Cardiac arrhythmias in patients with COVID-19: Lessons from 2300 458 telemetric monitoring days on the intensive care unit

AHA/ACC/HRS guideline for the management of patients with 461 atrial fibrillation: executive summary: a report of the American College of 462

Heart Association Task Force on practice guidelines and the Heart 463 Rhythm Society

Therapeutic Anticoagulation with Heparin in Noncritically Ill 465 Patients with Covid-19

COVID-19 and cardiac arrhythmias

Guidance on Short-Term Management of Atrial Fibrillation in 469

ASE Statement on Protection of Patients and Echocardiography 471 Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the 472

COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc 474 Med

Cardiac electrophysiology consultative experience at the epicenter of 476 the COVID-19 pandemic in the United States

In-hospital cardiac arrest outcomes among patients with COVID-19 479 pneumonia in Wuhan

Guidance for cardiac electrophysiology during the COVID-19 481 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology 482 Section of the American College of Cardiology

Arrhythmias Committee of the Council on Clinical Cardiology, American Heart 484 Association

Ventricular tachycardia 486 storm management in a COVID-19 patient: a case report

Bradyarrhythmias in patients with COVID-19: A case series

Heart block 492 in patients with coronavirus disease 2019: A case series of 3 patients infected with 493 SARS-CoV-2

Autonomic dysfunction following COVID-19 infection: an early 495 experience

Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of 497

Postural Orthostatic Tachycardia Syndrome: The Swedish Experience

Postural orthostatic tachycardia 500 syndrome

Post-Acute Sequelae of COVID-19 and Cardiovascular Autonomic 502 Dysfunction: What Do We Know?

Autonomic dysfunction post-acute COVID-19 infection

SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes

COVID-19 Infection Unmasking Brugada Syndrome. HeartRhythm 508 Case Rep

Brugada 510 syndrome, and COVID-19 lung disease

The Known Into the Unknown: Brugada 512 Syndrome and COVID-19

Intensive care and anesthetic management of patients with 514 Brugada syndrome and COVID-19 infection

COVID-19 Infection and Corrected QT Interval 517

Prolongation-Collateral Damage From Our Newest Enemy

Long QT syndrome-associated mutations in KCNQ1 and KCNE1 520 subunits disrupt normal endosomal recycling of IKs channels

Urgent Guidance 523 for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of 524

COVID-19)

Heritable arrhythmias associated with 527 abnormal function of cardiac potassium channels

COVID-19 pandemia and inherited cardiomyopathies and 530 channelopathies: a short term and long term perspective

Myocarditis and Other Cardiovascular Complications of the mRNA-533 Based COVID-19 Vaccines